MedPath

Replimune Submits BLA for RP1 Melanoma Treatment, Gains FDA Breakthrough Therapy Designation

• Replimune has submitted a Biologics License Application (BLA) to the FDA for RP1 in combination with nivolumab to treat advanced melanoma patients who have progressed on anti-PD-1 therapy. • The FDA granted Breakthrough Therapy designation to RP1, potentially accelerating its development and review for this patient population with limited treatment options. • The BLA submission is based on data from the IGNYTE trial, with a confirmatory Phase 3 trial (IGNYTE-3) currently enrolling patients to support full approval. • RP1, an oncolytic immunotherapy, is engineered to maximize tumor cell death and stimulate a systemic anti-tumor immune response, offering a novel approach to melanoma treatment.

Replimune Group, Inc. has announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of adult patients with advanced melanoma who have previously received an anti-PD-1 containing regimen. The FDA has granted Breakthrough Therapy designation to this combination, potentially expediting its development and review. The submission was made under the Accelerated Approval pathway, based on safety and clinical activity data from the IGNYTE clinical trial.

Breakthrough Therapy Designation

The Breakthrough Therapy designation is intended to expedite the development and review of therapies for serious diseases where preliminary clinical evidence indicates that the therapy may provide substantial improvement over existing available therapies on one or more clinically significant endpoints. This designation is based on the safety and clinical activity observed in the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial.

Clinical Data and Ongoing Trial

The BLA is supported by data from the IGNYTE clinical trial. A confirmatory Phase 3 IGNYTE-3 trial of RP1 in combination with nivolumab in advanced melanoma patients who have progressed on anti-PD-1 and anti-CTLA-4 therapy, or who are not candidates for anti-CTLA-4 treatment, is currently enrolling patients.

RP1: Oncolytic Immunotherapy

RP1 (vusolimogene oderparepvec) is Replimune’s lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF, intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response.

Executive Commentary

"Today is an important milestone for Replimune and for the melanoma community as we are one step closer to having another potential treatment available for patients who have limited options after progressing on anti-PD1 containing regimens," said Sushil Patel, Ph.D., CEO of Replimune.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Reviewing RP1 and Nivolumab Combination for Advanced Melanoma After PD-1 Inhibitor Failure

The FDA is evaluating a biologics license application for RP1 plus nivolumab to treat advanced melanoma in adults who have previously received a PD-1 inhibitor.
The application is supported by data from the phase 1/2 IGNYTE trial, which demonstrated an overall response rate of 32.7% in patients with anti-PD-1-failed melanoma.

Replimune's RP1 Receives FDA Breakthrough Therapy Designation and BLA Submission for Advanced Melanoma

Replimune has submitted a Biologics License Application (BLA) to the FDA for RP1 in combination with nivolumab to treat advanced melanoma patients after anti-PD-1 therapy.
The FDA granted Breakthrough Therapy designation to RP1 plus nivolumab, expediting its development for patients with limited options after anti-PD-1 regimen failure.

Replimune's RP1 Receives Priority Review from FDA for Advanced Melanoma

Replimune's BLA for RP1 in combination with Bristol Myers Squibb’s Opdivo to treat advanced melanoma has been accepted and granted priority review by the FDA.
The FDA's decision on the RP1/Opdivo combo is anticipated by July 22, 2025, with no advisory committee meeting planned currently.

FDA Considers Accelerated Approval for RP1 Plus Nivolumab in Advanced Melanoma

The FDA is reviewing a biologics license application for RP1 plus nivolumab to treat advanced melanoma after PD-1 inhibitor failure.
Phase 1/2 IGNYTE trial data showed a 32.7% overall response rate in patients treated with the combination therapy.

FDA Grants Breakthrough Therapy Designation to RP1 Plus Nivolumab for Advanced Melanoma

The FDA granted Breakthrough Therapy Designation to vusolimogene oderparepvec (RP1) combined with nivolumab for advanced melanoma after anti-PD-1 therapy failure.
A Biologics License Application (BLA) has been submitted for RP1 with nivolumab under the Accelerated Approval pathway for previously treated advanced melanoma.

FDA Grants Fast Track Designation to Immuneering's IMM-1-104 for Advanced Melanoma

The FDA has granted Fast Track designation to Immuneering's IMM-1-104 for unresectable or metastatic NRAS-mutant melanoma treatment.
IMM-1-104 is currently in Phase 2a clinical trials, showing unique tolerability compared to existing MEK inhibitors in Phase 1 data.

Replimune's RP1 Receives FDA Breakthrough Therapy Designation for Advanced Melanoma

Replimune's RP1, combined with nivolumab, has been granted Breakthrough Therapy designation by the FDA for advanced melanoma after anti-PD-1 treatment failure.
The BLA submission to the FDA for RP1 in combination with nivolumab was made under the Accelerated Approval pathway.

Replimune's RP1 Receives FDA Breakthrough Therapy Designation for Advanced Melanoma

Replimune's RP1 (vusolimogene oderparepvec) has been granted Breakthrough Therapy designation by the FDA for advanced melanoma treatment.
The BLA for RP1 in combination with nivolumab has been submitted to the FDA under the Accelerated Approval pathway.

Moleculin Biotech's Annamycin Advances to Phase 3 Trial for Relapsed/Refractory AML

Moleculin Biotech's Annamycin receives IRB approval to begin a Phase 3 clinical trial (MIRACLE) for relapsed or refractory AML.
The MIRACLE trial will evaluate Annamycin in combination with cytarabine, with potential for accelerated FDA approval.

Replimune's RP1 Receives Positive FDA Feedback for Melanoma Treatment

Replimune completed a successful pre-BLA meeting with the FDA for RP1 in anti-PD1 failed melanoma, supporting an accelerated approval pathway.
The IGNYTE clinical trial showed a 33% overall response rate when RP1 was combined with nivolumab in patients with advanced melanoma.

Reference News

[1]
Replimune Seeks FDA Approval for Breakthrough Melanoma Treatment RP1 - Stock Titan
stocktitan.net · Nov 21, 2024

Replimune submitted a BLA to the FDA for RP1 in combination with nivolumab to treat advanced melanoma patients previousl...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy